Stephen Waldo
Concepts (419)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Percutaneous Coronary Intervention | 77 | 2025 | 543 | 17.990 |
Why?
| | Coronary Artery Disease | 45 | 2025 | 741 | 10.360 |
Why?
| | United States Department of Veterans Affairs | 33 | 2025 | 768 | 5.560 |
Why?
| | Coronary Angiography | 31 | 2025 | 323 | 3.540 |
Why?
| | Peripheral Arterial Disease | 25 | 2020 | 503 | 3.190 |
Why?
| | Myocardial Infarction | 29 | 2025 | 1209 | 3.150 |
Why?
| | Endovascular Procedures | 18 | 2020 | 384 | 2.950 |
Why?
| | Femoral Artery | 13 | 2022 | 190 | 2.660 |
Why?
| | Acute Coronary Syndrome | 8 | 2025 | 293 | 2.630 |
Why?
| | Treatment Outcome | 91 | 2025 | 11695 | 2.550 |
Why?
| | Veterans | 18 | 2025 | 1603 | 2.550 |
Why?
| | Vascular Calcification | 9 | 2022 | 110 | 2.320 |
Why?
| | Veterans Health | 7 | 2025 | 189 | 2.230 |
Why?
| | Stents | 21 | 2019 | 556 | 2.170 |
Why?
| | ST Elevation Myocardial Infarction | 6 | 2022 | 63 | 2.080 |
Why?
| | Popliteal Artery | 11 | 2020 | 62 | 2.070 |
Why?
| | Atherectomy | 11 | 2022 | 37 | 1.910 |
Why?
| | Myocardial Ischemia | 6 | 2025 | 285 | 1.900 |
Why?
| | Risk Factors | 70 | 2025 | 10792 | 1.870 |
Why?
| | Coronary Artery Bypass | 8 | 2025 | 269 | 1.870 |
Why?
| | Registries | 28 | 2023 | 2385 | 1.830 |
Why?
| | United States | 64 | 2026 | 15988 | 1.750 |
Why?
| | Ischemia | 11 | 2020 | 421 | 1.720 |
Why?
| | Atherectomy, Coronary | 5 | 2022 | 10 | 1.660 |
Why?
| | Time Factors | 52 | 2025 | 7183 | 1.660 |
Why?
| | Risk Assessment | 29 | 2025 | 3676 | 1.620 |
Why?
| | Aged | 89 | 2026 | 25947 | 1.610 |
Why?
| | Platelet Aggregation Inhibitors | 8 | 2025 | 497 | 1.540 |
Why?
| | Radial Artery | 7 | 2022 | 70 | 1.520 |
Why?
| | Lower Extremity | 4 | 2018 | 438 | 1.500 |
Why?
| | Angioplasty, Balloon, Coronary | 6 | 2017 | 158 | 1.490 |
Why?
| | Time-to-Treatment | 5 | 2024 | 245 | 1.470 |
Why?
| | Hospitals, Veterans | 5 | 2025 | 259 | 1.360 |
Why?
| | Middle Aged | 82 | 2025 | 35928 | 1.340 |
Why?
| | Cardiovascular Agents | 7 | 2023 | 164 | 1.300 |
Why?
| | Humans | 160 | 2026 | 144957 | 1.300 |
Why?
| | Non-ST Elevated Myocardial Infarction | 3 | 2020 | 25 | 1.250 |
Why?
| | Biological Products | 2 | 2023 | 252 | 1.220 |
Why?
| | Hospital Mortality | 13 | 2025 | 1031 | 1.210 |
Why?
| | Male | 103 | 2026 | 72406 | 1.170 |
Why?
| | Coronary Restenosis | 4 | 2017 | 22 | 1.160 |
Why?
| | Coronary Vessels | 7 | 2025 | 251 | 1.150 |
Why?
| | Angioplasty, Balloon | 9 | 2020 | 94 | 1.130 |
Why?
| | Female | 97 | 2026 | 78376 | 1.060 |
Why?
| | Myocardial Revascularization | 3 | 2019 | 85 | 1.040 |
Why?
| | Access to Information | 2 | 2019 | 48 | 1.030 |
Why?
| | Retrospective Studies | 54 | 2026 | 17101 | 1.020 |
Why?
| | Catheterization, Peripheral | 2 | 2019 | 119 | 0.990 |
Why?
| | Stroke Volume | 4 | 2026 | 651 | 0.950 |
Why?
| | Surgical Procedures, Operative | 3 | 2025 | 271 | 0.920 |
Why?
| | Angina, Stable | 3 | 2022 | 18 | 0.900 |
Why?
| | Exercise Test | 3 | 2025 | 634 | 0.900 |
Why?
| | Patient Readmission | 9 | 2025 | 759 | 0.880 |
Why?
| | Eligibility Determination | 1 | 2025 | 68 | 0.870 |
Why?
| | Coated Materials, Biocompatible | 6 | 2020 | 65 | 0.850 |
Why?
| | Natural Language Processing | 1 | 2025 | 103 | 0.840 |
Why?
| | Quality Improvement | 5 | 2025 | 1291 | 0.820 |
Why?
| | Delivery of Health Care, Integrated | 2 | 2025 | 299 | 0.810 |
Why?
| | Quality of Health Care | 3 | 2025 | 693 | 0.810 |
Why?
| | Cardiology | 4 | 2022 | 353 | 0.810 |
Why?
| | Myocardial Reperfusion | 2 | 2013 | 59 | 0.800 |
Why?
| | Community Health Services | 1 | 2025 | 234 | 0.780 |
Why?
| | Cardiac Catheterization | 5 | 2025 | 560 | 0.770 |
Why?
| | Vascular Patency | 14 | 2020 | 121 | 0.760 |
Why?
| | Ventricular Function, Left | 3 | 2021 | 541 | 0.750 |
Why?
| | Chickens | 1 | 2023 | 191 | 0.750 |
Why?
| | Coronary Thrombosis | 4 | 2015 | 25 | 0.720 |
Why?
| | Heart Arrest | 3 | 2017 | 407 | 0.710 |
Why?
| | Vascular Access Devices | 5 | 2020 | 30 | 0.710 |
Why?
| | Elective Surgical Procedures | 2 | 2020 | 201 | 0.710 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 5 | 2023 | 439 | 0.700 |
Why?
| | Psoriasis | 1 | 2023 | 112 | 0.700 |
Why?
| | California | 18 | 2019 | 475 | 0.690 |
Why?
| | Healthcare Disparities | 3 | 2024 | 728 | 0.690 |
Why?
| | Anemia | 2 | 2022 | 188 | 0.670 |
Why?
| | Practice Patterns, Physicians' | 7 | 2025 | 1358 | 0.670 |
Why?
| | Coronary Occlusion | 2 | 2023 | 20 | 0.670 |
Why?
| | Aged, 80 and over | 23 | 2025 | 8279 | 0.660 |
Why?
| | Heart Failure, Systolic | 1 | 2021 | 27 | 0.660 |
Why?
| | Patient Selection | 1 | 2025 | 719 | 0.660 |
Why?
| | Drug-Eluting Stents | 6 | 2017 | 88 | 0.620 |
Why?
| | Hospitals, Community | 1 | 2020 | 65 | 0.620 |
Why?
| | Hemorrhage | 5 | 2022 | 809 | 0.610 |
Why?
| | Assisted Circulation | 1 | 2019 | 26 | 0.610 |
Why?
| | Paclitaxel | 2 | 2019 | 256 | 0.610 |
Why?
| | Electronic Health Records | 3 | 2025 | 1177 | 0.600 |
Why?
| | Hemostatic Techniques | 1 | 2020 | 51 | 0.600 |
Why?
| | Cardiovascular Diseases | 4 | 2025 | 2171 | 0.600 |
Why?
| | Embolic Protection Devices | 1 | 2019 | 12 | 0.590 |
Why?
| | Quality Indicators, Health Care | 4 | 2025 | 335 | 0.580 |
Why?
| | Saphenous Vein | 1 | 2019 | 37 | 0.580 |
Why?
| | Intra-Aortic Balloon Pumping | 1 | 2019 | 19 | 0.580 |
Why?
| | Graft Occlusion, Vascular | 1 | 2019 | 42 | 0.580 |
Why?
| | Postoperative Hemorrhage | 1 | 2020 | 104 | 0.570 |
Why?
| | Heart Failure | 7 | 2026 | 2323 | 0.570 |
Why?
| | Databases, Factual | 11 | 2025 | 1486 | 0.560 |
Why?
| | Postoperative Complications | 5 | 2025 | 2920 | 0.560 |
Why?
| | Fibrinolytic Agents | 2 | 2018 | 292 | 0.560 |
Why?
| | Cardiac Surgical Procedures | 2 | 2022 | 609 | 0.560 |
Why?
| | Electrocardiography | 4 | 2015 | 663 | 0.550 |
Why?
| | Arterial Occlusive Diseases | 1 | 2018 | 90 | 0.540 |
Why?
| | Arm | 1 | 2018 | 110 | 0.530 |
Why?
| | Odds Ratio | 8 | 2021 | 1077 | 0.530 |
Why?
| | Peripheral Vascular Diseases | 1 | 2018 | 104 | 0.530 |
Why?
| | Thromboembolism | 1 | 2018 | 125 | 0.520 |
Why?
| | Cerebrovascular Disorders | 1 | 2018 | 103 | 0.510 |
Why?
| | Kaplan-Meier Estimate | 12 | 2020 | 966 | 0.510 |
Why?
| | Limb Salvage | 7 | 2019 | 70 | 0.510 |
Why?
| | Propensity Score | 6 | 2024 | 367 | 0.510 |
Why?
| | Renal Artery Obstruction | 1 | 2017 | 29 | 0.500 |
Why?
| | Embolism | 1 | 2017 | 48 | 0.500 |
Why?
| | Renal Artery | 1 | 2017 | 43 | 0.490 |
Why?
| | Aspirin | 2 | 2019 | 400 | 0.490 |
Why?
| | Research Report | 1 | 2017 | 87 | 0.490 |
Why?
| | Contrast Media | 4 | 2025 | 488 | 0.490 |
Why?
| | Hospitals | 4 | 2023 | 732 | 0.480 |
Why?
| | Transcatheter Aortic Valve Replacement | 3 | 2025 | 152 | 0.470 |
Why?
| | Catheterization | 3 | 2021 | 183 | 0.470 |
Why?
| | Coronary Stenosis | 5 | 2020 | 38 | 0.450 |
Why?
| | Iliac Artery | 4 | 2019 | 55 | 0.440 |
Why?
| | Hospitalization | 4 | 2025 | 2434 | 0.430 |
Why?
| | Disclosure | 1 | 2015 | 85 | 0.430 |
Why?
| | Hypertension, Pulmonary | 5 | 2025 | 1980 | 0.420 |
Why?
| | Risk Reduction Behavior | 1 | 2016 | 226 | 0.420 |
Why?
| | Cell Separation | 1 | 2015 | 307 | 0.410 |
Why?
| | Survival Rate | 7 | 2026 | 2092 | 0.410 |
Why?
| | Atherosclerosis | 3 | 2019 | 409 | 0.400 |
Why?
| | Thrombectomy | 2 | 2014 | 78 | 0.400 |
Why?
| | Cohort Studies | 10 | 2023 | 5965 | 0.400 |
Why?
| | Depressive Disorder | 1 | 2017 | 387 | 0.400 |
Why?
| | Cardiologists | 2 | 2025 | 47 | 0.380 |
Why?
| | Vascular Surgical Procedures | 1 | 2016 | 340 | 0.380 |
Why?
| | Disease Management | 1 | 2017 | 647 | 0.370 |
Why?
| | Predictive Value of Tests | 9 | 2025 | 2118 | 0.370 |
Why?
| | Acute Kidney Injury | 5 | 2025 | 866 | 0.370 |
Why?
| | Incidence | 8 | 2025 | 2883 | 0.360 |
Why?
| | Peer Review | 2 | 2025 | 44 | 0.360 |
Why?
| | HIV | 1 | 2013 | 250 | 0.360 |
Why?
| | Logistic Models | 6 | 2017 | 2119 | 0.350 |
Why?
| | Intermittent Claudication | 3 | 2017 | 121 | 0.350 |
Why?
| | Attitude of Health Personnel | 1 | 2019 | 1186 | 0.340 |
Why?
| | Hypothermia | 1 | 2011 | 52 | 0.330 |
Why?
| | Hemodynamics | 5 | 2026 | 1121 | 0.330 |
Why?
| | Out-of-Hospital Cardiac Arrest | 2 | 2024 | 124 | 0.320 |
Why?
| | Cause of Death | 3 | 2023 | 472 | 0.320 |
Why?
| | Stroke | 7 | 2025 | 1258 | 0.320 |
Why?
| | Severity of Illness Index | 8 | 2025 | 2925 | 0.310 |
Why?
| | Aortic Valve Stenosis | 2 | 2025 | 253 | 0.300 |
Why?
| | Constriction, Pathologic | 9 | 2020 | 248 | 0.290 |
Why?
| | Mentoring | 2 | 2023 | 166 | 0.290 |
Why?
| | Proportional Hazards Models | 9 | 2023 | 1325 | 0.290 |
Why?
| | Peptide Fragments | 2 | 2015 | 699 | 0.290 |
Why?
| | Chi-Square Distribution | 4 | 2018 | 529 | 0.290 |
Why?
| | Mortality | 3 | 2020 | 376 | 0.290 |
Why?
| | Endothelial Cells | 1 | 2015 | 870 | 0.280 |
Why?
| | Punctures | 2 | 2019 | 40 | 0.280 |
Why?
| | Angiography | 6 | 2020 | 208 | 0.280 |
Why?
| | Laser Therapy | 2 | 2019 | 135 | 0.270 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2008 | 111 | 0.260 |
Why?
| | Carotid Stenosis | 2 | 2018 | 102 | 0.250 |
Why?
| | Myocardial Perfusion Imaging | 2 | 2019 | 49 | 0.250 |
Why?
| | Cardiac Output, High | 1 | 2026 | 1 | 0.240 |
Why?
| | Recurrence | 9 | 2019 | 1135 | 0.240 |
Why?
| | Sex Factors | 5 | 2025 | 2114 | 0.240 |
Why?
| | Follow-Up Studies | 7 | 2026 | 5417 | 0.240 |
Why?
| | Emergency Medical Services | 1 | 2013 | 696 | 0.240 |
Why?
| | Multivariate Analysis | 5 | 2017 | 1540 | 0.230 |
Why?
| | Ventricular Dysfunction, Left | 2 | 2021 | 392 | 0.230 |
Why?
| | HIV Infections | 3 | 2023 | 3154 | 0.230 |
Why?
| | Macrophages | 3 | 2008 | 1511 | 0.230 |
Why?
| | Purinergic P2Y Receptor Antagonists | 2 | 2023 | 69 | 0.230 |
Why?
| | Acute Disease | 3 | 2017 | 1031 | 0.230 |
Why?
| | Cytochrome P-450 CYP2C19 | 1 | 2025 | 26 | 0.220 |
Why?
| | Ultrasonography, Interventional | 2 | 2025 | 160 | 0.220 |
Why?
| | Patient Discharge | 3 | 2022 | 983 | 0.220 |
Why?
| | Peer Review, Health Care | 1 | 2025 | 4 | 0.220 |
Why?
| | Renal Insufficiency, Chronic | 2 | 2023 | 653 | 0.220 |
Why?
| | Chest Pain | 3 | 2022 | 100 | 0.220 |
Why?
| | Chemokine CXCL12 | 1 | 2025 | 89 | 0.220 |
Why?
| | Tomography, Optical Coherence | 2 | 2025 | 271 | 0.210 |
Why?
| | Travel | 1 | 2025 | 136 | 0.210 |
Why?
| | Comorbidity | 5 | 2020 | 1660 | 0.210 |
Why?
| | Pancreas | 2 | 2004 | 342 | 0.210 |
Why?
| | Prosthesis Failure | 2 | 2016 | 128 | 0.200 |
Why?
| | Health Services Accessibility | 2 | 2025 | 1099 | 0.200 |
Why?
| | Hypertension, Portal | 1 | 2024 | 66 | 0.200 |
Why?
| | Hypothermia, Induced | 1 | 2024 | 96 | 0.200 |
Why?
| | Coronary Circulation | 2 | 2014 | 136 | 0.190 |
Why?
| | Fractional Flow Reserve, Myocardial | 2 | 2020 | 9 | 0.190 |
Why?
| | Biological Therapy | 1 | 2023 | 28 | 0.190 |
Why?
| | Heart Valve Prosthesis Implantation | 1 | 2025 | 197 | 0.190 |
Why?
| | Cross-Sectional Studies | 6 | 2022 | 5872 | 0.190 |
Why?
| | New York | 3 | 2017 | 127 | 0.190 |
Why?
| | Work Engagement | 1 | 2022 | 14 | 0.180 |
Why?
| | Prognosis | 6 | 2021 | 4293 | 0.180 |
Why?
| | Chronic Disease | 5 | 2023 | 1813 | 0.180 |
Why?
| | Leukocytes | 1 | 2003 | 295 | 0.180 |
Why?
| | Technology Transfer | 1 | 2021 | 9 | 0.170 |
Why?
| | Clinical Decision-Making | 1 | 2025 | 359 | 0.170 |
Why?
| | Social Class | 1 | 2023 | 268 | 0.170 |
Why?
| | Critical Illness | 8 | 2020 | 892 | 0.170 |
Why?
| | Shock, Cardiogenic | 2 | 2021 | 64 | 0.160 |
Why?
| | Angina Pectoris | 1 | 2020 | 75 | 0.160 |
Why?
| | Aftercare | 1 | 2022 | 224 | 0.160 |
Why?
| | Mandatory Reporting | 2 | 2017 | 47 | 0.160 |
Why?
| | Anticoagulants | 2 | 2016 | 724 | 0.160 |
Why?
| | Thrombocytopenia | 1 | 2022 | 205 | 0.160 |
Why?
| | Massachusetts | 2 | 2017 | 180 | 0.150 |
Why?
| | Patient Care Team | 1 | 2025 | 689 | 0.150 |
Why?
| | Genome-Wide Association Study | 2 | 2025 | 1407 | 0.150 |
Why?
| | Delivery of Health Care | 2 | 2023 | 947 | 0.150 |
Why?
| | Echocardiography, Stress | 1 | 2019 | 29 | 0.150 |
Why?
| | Vascular Resistance | 1 | 2020 | 367 | 0.150 |
Why?
| | Referral and Consultation | 1 | 2025 | 853 | 0.150 |
Why?
| | Health Facilities | 1 | 2019 | 85 | 0.150 |
Why?
| | Intraoperative Period | 1 | 2019 | 69 | 0.140 |
Why?
| | Ambulatory Surgical Procedures | 1 | 2019 | 80 | 0.140 |
Why?
| | Fluid Therapy | 1 | 2020 | 147 | 0.140 |
Why?
| | Heart | 1 | 2022 | 636 | 0.140 |
Why?
| | Centralized Hospital Services | 1 | 2018 | 6 | 0.140 |
Why?
| | Socioeconomic Factors | 1 | 2023 | 1327 | 0.140 |
Why?
| | Thrombosis | 1 | 2022 | 393 | 0.140 |
Why?
| | Colorado | 8 | 2019 | 4564 | 0.140 |
Why?
| | Angioplasty, Balloon, Laser-Assisted | 1 | 2017 | 1 | 0.140 |
Why?
| | Secondary Prevention | 1 | 2019 | 255 | 0.140 |
Why?
| | Biomarkers | 4 | 2017 | 4275 | 0.140 |
Why?
| | Pregnancy-Associated Plasma Protein-A | 1 | 2017 | 14 | 0.130 |
Why?
| | Angioplasty | 1 | 2018 | 50 | 0.130 |
Why?
| | Perception | 1 | 2021 | 377 | 0.130 |
Why?
| | Disease-Free Survival | 5 | 2017 | 769 | 0.130 |
Why?
| | Cardiac Catheters | 1 | 2017 | 16 | 0.130 |
Why?
| | Transportation of Patients | 1 | 2018 | 68 | 0.130 |
Why?
| | Perioperative Care | 1 | 2020 | 231 | 0.130 |
Why?
| | Rosuvastatin Calcium | 1 | 2017 | 21 | 0.130 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2023 | 2584 | 0.130 |
Why?
| | Macrophage Colony-Stimulating Factor | 2 | 2008 | 19 | 0.130 |
Why?
| | ADAMTS13 Protein | 1 | 2017 | 7 | 0.130 |
Why?
| | Pulmonary Artery | 1 | 2023 | 1134 | 0.130 |
Why?
| | Algorithms | 2 | 2017 | 1839 | 0.130 |
Why?
| | Thrombotic Microangiopathies | 1 | 2017 | 19 | 0.130 |
Why?
| | Neck | 1 | 2017 | 108 | 0.130 |
Why?
| | Computer Simulation | 1 | 2021 | 1026 | 0.130 |
Why?
| | Ankle Brachial Index | 1 | 2017 | 41 | 0.130 |
Why?
| | Risk | 2 | 2019 | 911 | 0.130 |
Why?
| | Suction | 2 | 2014 | 33 | 0.120 |
Why?
| | Policy Making | 1 | 2017 | 82 | 0.120 |
Why?
| | Reproducibility of Results | 5 | 2025 | 3415 | 0.120 |
Why?
| | Clinical Competence | 1 | 2025 | 1244 | 0.120 |
Why?
| | Flow Cytometry | 2 | 2015 | 1173 | 0.120 |
Why?
| | Aortic Valve | 1 | 2019 | 365 | 0.120 |
Why?
| | Health Services Needs and Demand | 1 | 2018 | 280 | 0.120 |
Why?
| | Boston | 1 | 2016 | 92 | 0.120 |
Why?
| | Academic Medical Centers | 2 | 2016 | 548 | 0.120 |
Why?
| | Adult | 7 | 2024 | 40506 | 0.120 |
Why?
| | Dyslipidemias | 1 | 2017 | 182 | 0.110 |
Why?
| | Burnout, Professional | 1 | 2022 | 484 | 0.110 |
Why?
| | Pandemics | 2 | 2021 | 1695 | 0.110 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 2 | 2007 | 210 | 0.110 |
Why?
| | Cholesterol | 2 | 2008 | 408 | 0.110 |
Why?
| | Contraindications | 1 | 2014 | 91 | 0.110 |
Why?
| | Gene Expression Profiling | 2 | 2015 | 1786 | 0.110 |
Why?
| | Aortic Diseases | 1 | 2016 | 124 | 0.110 |
Why?
| | Antithrombins | 1 | 2015 | 70 | 0.110 |
Why?
| | Collateral Circulation | 1 | 2014 | 19 | 0.110 |
Why?
| | Models, Cardiovascular | 1 | 2015 | 195 | 0.110 |
Why?
| | Prevalence | 2 | 2019 | 2836 | 0.100 |
Why?
| | Heparin | 1 | 2015 | 244 | 0.100 |
Why?
| | Observer Variation | 3 | 2025 | 355 | 0.100 |
Why?
| | Prospective Studies | 3 | 2020 | 7997 | 0.100 |
Why?
| | Incidental Findings | 1 | 2013 | 80 | 0.100 |
Why?
| | Diabetes Mellitus | 2 | 2018 | 1098 | 0.090 |
Why?
| | Resuscitation | 1 | 2015 | 302 | 0.090 |
Why?
| | Primary Prevention | 1 | 2014 | 220 | 0.090 |
Why?
| | Smoking Cessation | 1 | 2016 | 439 | 0.090 |
Why?
| | Coronary Disease | 1 | 2014 | 386 | 0.090 |
Why?
| | Trazodone | 1 | 2011 | 2 | 0.090 |
Why?
| | Antimanic Agents | 1 | 2011 | 19 | 0.090 |
Why?
| | Glucagon-Like Peptide-1 Receptor | 2 | 2023 | 88 | 0.090 |
Why?
| | Lithium | 1 | 2011 | 42 | 0.090 |
Why?
| | Triazines | 1 | 2011 | 49 | 0.090 |
Why?
| | Laboratories | 2 | 2022 | 109 | 0.080 |
Why?
| | American Heart Association | 2 | 2022 | 350 | 0.080 |
Why?
| | Prosthesis Design | 3 | 2017 | 357 | 0.080 |
Why?
| | Decision Support Techniques | 1 | 2014 | 456 | 0.080 |
Why?
| | Benzodiazepines | 1 | 2011 | 168 | 0.080 |
Why?
| | Age Factors | 4 | 2019 | 3335 | 0.070 |
Why?
| | Lipoproteins, LDL | 2 | 2007 | 119 | 0.070 |
Why?
| | Cell Differentiation | 2 | 2008 | 2050 | 0.070 |
Why?
| | Anticonvulsants | 1 | 2011 | 242 | 0.070 |
Why?
| | Bipolar Disorder | 1 | 2011 | 280 | 0.070 |
Why?
| | MicroRNAs | 1 | 2015 | 701 | 0.070 |
Why?
| | Depression | 1 | 2018 | 1559 | 0.070 |
Why?
| | Pinocytosis | 1 | 2007 | 6 | 0.070 |
Why?
| | Ultrasonography, Doppler, Duplex | 2 | 2017 | 40 | 0.070 |
Why?
| | Monocytes | 2 | 2007 | 538 | 0.070 |
Why?
| | Area Under Curve | 1 | 2008 | 331 | 0.070 |
Why?
| | Seizures | 1 | 2011 | 477 | 0.060 |
Why?
| | Animals | 4 | 2025 | 38109 | 0.060 |
Why?
| | Fluorescent Antibody Technique | 1 | 2008 | 370 | 0.060 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2008 | 161 | 0.060 |
Why?
| | Adrenergic beta-Antagonists | 2 | 2019 | 250 | 0.060 |
Why?
| | Drug Overdose | 1 | 2011 | 370 | 0.060 |
Why?
| | Phenotype | 2 | 2021 | 3164 | 0.060 |
Why?
| | ROC Curve | 1 | 2008 | 615 | 0.060 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2025 | 2147 | 0.060 |
Why?
| | Inflammation | 3 | 2008 | 2880 | 0.060 |
Why?
| | Equipment Design | 2 | 2018 | 530 | 0.060 |
Why?
| | Shock | 2 | 2004 | 108 | 0.060 |
Why?
| | Polymerase Chain Reaction | 1 | 2008 | 1054 | 0.050 |
Why?
| | Program Evaluation | 2 | 2019 | 949 | 0.050 |
Why?
| | Health Plan Implementation | 1 | 2025 | 136 | 0.050 |
Why?
| | Ventricular Fibrillation | 1 | 2024 | 64 | 0.050 |
Why?
| | Survival Analysis | 2 | 2020 | 1385 | 0.050 |
Why?
| | Lipid Metabolism | 1 | 2008 | 528 | 0.050 |
Why?
| | Trypsin | 1 | 2004 | 76 | 0.050 |
Why?
| | Exercise | 1 | 2016 | 2201 | 0.050 |
Why?
| | Amylases | 1 | 2003 | 18 | 0.050 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2004 | 132 | 0.050 |
Why?
| | Chymotrypsin | 1 | 2003 | 23 | 0.050 |
Why?
| | Ezetimibe | 1 | 2023 | 24 | 0.050 |
Why?
| | Length of Stay | 2 | 2019 | 1337 | 0.050 |
Why?
| | Tissue Distribution | 1 | 2003 | 334 | 0.050 |
Why?
| | Tachycardia, Ventricular | 1 | 2024 | 181 | 0.050 |
Why?
| | Drug Therapy, Combination | 2 | 2016 | 1048 | 0.050 |
Why?
| | Hypoglycemic Agents | 2 | 2023 | 1389 | 0.050 |
Why?
| | Polymorphism, Genetic | 1 | 2025 | 612 | 0.050 |
Why?
| | Glucagon-Like Peptide 1 | 1 | 2023 | 146 | 0.050 |
Why?
| | Pancreatitis | 1 | 2003 | 145 | 0.050 |
Why?
| | Rats, Wistar | 1 | 2003 | 451 | 0.050 |
Why?
| | Personnel Turnover | 1 | 2022 | 42 | 0.040 |
Why?
| | Practice Guidelines as Topic | 2 | 2020 | 1563 | 0.040 |
Why?
| | Liver Cirrhosis | 1 | 2024 | 288 | 0.040 |
Why?
| | Cell Death | 1 | 2003 | 383 | 0.040 |
Why?
| | Cholesterol, LDL | 1 | 2023 | 358 | 0.040 |
Why?
| | Reperfusion Injury | 1 | 2004 | 300 | 0.040 |
Why?
| | Troponin | 1 | 2021 | 49 | 0.040 |
Why?
| | Neutrophils | 2 | 2004 | 1134 | 0.040 |
Why?
| | Consensus | 1 | 2023 | 489 | 0.040 |
Why?
| | Organizational Culture | 1 | 2022 | 162 | 0.040 |
Why?
| | Disease Progression | 2 | 2019 | 2852 | 0.040 |
Why?
| | Systole | 1 | 2021 | 178 | 0.040 |
Why?
| | Inpatients | 1 | 2025 | 546 | 0.040 |
Why?
| | Cells, Cultured | 1 | 2008 | 4155 | 0.040 |
Why?
| | Ambulatory Care | 1 | 2025 | 603 | 0.040 |
Why?
| | Genotype | 1 | 2025 | 1835 | 0.040 |
Why?
| | Free Radical Scavengers | 1 | 2020 | 82 | 0.040 |
Why?
| | Cytokines | 1 | 2008 | 2065 | 0.040 |
Why?
| | Sodium Bicarbonate | 1 | 2020 | 47 | 0.040 |
Why?
| | DNA-Binding Proteins | 1 | 2007 | 1500 | 0.040 |
Why?
| | Job Satisfaction | 1 | 2022 | 240 | 0.040 |
Why?
| | Sodium | 1 | 2020 | 197 | 0.040 |
Why?
| | Acetylcysteine | 1 | 2020 | 139 | 0.040 |
Why?
| | Hospitals, High-Volume | 1 | 2019 | 49 | 0.040 |
Why?
| | Exercise Tolerance | 1 | 2021 | 283 | 0.040 |
Why?
| | Cost Savings | 1 | 2019 | 86 | 0.040 |
Why?
| | Endocrinologists | 1 | 2018 | 11 | 0.040 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2019 | 114 | 0.040 |
Why?
| | Drug Utilization | 1 | 2019 | 167 | 0.040 |
Why?
| | Retreatment | 1 | 2018 | 77 | 0.040 |
Why?
| | Hypertension | 2 | 2018 | 1264 | 0.040 |
Why?
| | Comparative Effectiveness Research | 1 | 2019 | 170 | 0.030 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2019 | 222 | 0.030 |
Why?
| | Rats | 2 | 2004 | 5614 | 0.030 |
Why?
| | Singapore | 1 | 2017 | 27 | 0.030 |
Why?
| | Republic of Korea | 1 | 2017 | 42 | 0.030 |
Why?
| | Transcription Factors | 1 | 2006 | 1742 | 0.030 |
Why?
| | Angina, Unstable | 1 | 2017 | 82 | 0.030 |
Why?
| | Purpura, Thrombotic Thrombocytopenic | 1 | 2017 | 14 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2020 | 1268 | 0.030 |
Why?
| | New Jersey | 1 | 2016 | 16 | 0.030 |
Why?
| | Michigan | 1 | 2016 | 136 | 0.030 |
Why?
| | Glomerular Filtration Rate | 1 | 2020 | 760 | 0.030 |
Why?
| | Aortography | 1 | 2016 | 52 | 0.030 |
Why?
| | Platelet Aggregation | 1 | 2016 | 105 | 0.030 |
Why?
| | Postoperative Care | 1 | 2017 | 288 | 0.030 |
Why?
| | Glucose | 1 | 2020 | 1049 | 0.030 |
Why?
| | Guideline Adherence | 1 | 2019 | 589 | 0.030 |
Why?
| | Linear Models | 1 | 2017 | 854 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2021 | 1721 | 0.030 |
Why?
| | Drug Prescriptions | 1 | 2017 | 285 | 0.030 |
Why?
| | Hirudins | 1 | 2015 | 51 | 0.030 |
Why?
| | Blood Transfusion | 1 | 2017 | 405 | 0.030 |
Why?
| | Blood Coagulation | 1 | 2016 | 268 | 0.030 |
Why?
| | Protective Factors | 1 | 2014 | 99 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2019 | 1054 | 0.030 |
Why?
| | Genetic Predisposition to Disease | 1 | 2022 | 2365 | 0.020 |
Why?
| | Health Policy | 1 | 2016 | 401 | 0.020 |
Why?
| | Blood Flow Velocity | 1 | 2014 | 413 | 0.020 |
Why?
| | Emergencies | 1 | 2013 | 176 | 0.020 |
Why?
| | Lipids | 1 | 2017 | 710 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2015 | 1371 | 0.020 |
Why?
| | Cost-Benefit Analysis | 1 | 2014 | 636 | 0.020 |
Why?
| | Health Care Costs | 1 | 2014 | 427 | 0.020 |
Why?
| | Kidney Failure, Chronic | 1 | 2017 | 598 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2018 | 2947 | 0.020 |
Why?
| | Models, Biological | 1 | 2017 | 1822 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2022 | 6053 | 0.020 |
Why?
| | Medicare | 1 | 2014 | 887 | 0.020 |
Why?
| | Clofibrate | 1 | 2007 | 3 | 0.020 |
Why?
| | Orphan Nuclear Receptors | 1 | 2007 | 14 | 0.020 |
Why?
| | Hydrocarbons, Fluorinated | 1 | 2007 | 8 | 0.020 |
Why?
| | Peroxisome Proliferator-Activated Receptors | 1 | 2007 | 17 | 0.020 |
Why?
| | Liver X Receptors | 1 | 2007 | 30 | 0.020 |
Why?
| | beta-Cyclodextrins | 1 | 2007 | 32 | 0.020 |
Why?
| | Mice | 1 | 2025 | 18365 | 0.020 |
Why?
| | Fluorocarbons | 1 | 2007 | 143 | 0.010 |
Why?
| | Down-Regulation | 1 | 2007 | 627 | 0.010 |
Why?
| | Physicians | 1 | 2013 | 940 | 0.010 |
Why?
| | Mesenteric Arteries | 1 | 2004 | 18 | 0.010 |
Why?
| | Jejunum | 1 | 2004 | 35 | 0.010 |
Why?
| | Interleukin-10 | 1 | 2006 | 310 | 0.010 |
Why?
| | Telemedicine | 1 | 2013 | 948 | 0.010 |
Why?
| | Gelatin | 1 | 2004 | 56 | 0.010 |
Why?
| | Peroxidase | 1 | 2004 | 168 | 0.010 |
Why?
| | Sulfonamides | 1 | 2007 | 581 | 0.010 |
Why?
| | Microscopy, Fluorescence | 1 | 2004 | 418 | 0.010 |
Why?
| | Enzyme Activation | 1 | 2004 | 768 | 0.010 |
Why?
| | Blotting, Western | 1 | 2004 | 1187 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2004 | 2540 | 0.010 |
Why?
|
|
Waldo's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|